CLINICAL TRIAL

Xylitol for Cross Infection

Waitlist Available · Any Age · All Sexes · Cincinnati, OH

This study is evaluating whether a daily dental wipe with xylitol may help reduce the risk of oral infections for individuals who have undergone stem cell transplant.

See full description

About the trial for Cross Infection

Eligible Conditions
Cross Infection · Allogeneic Hematopoietic Cell Transplantation (HCT)

Treatment Groups

This trial involves 2 different treatments. Xylitol is the primary treatment being studied. Participants will all receive the same treatment. Some patients will receive a placebo treatment. The treatments being tested are in Phase 2 and have already been tested with other people.

Main TreatmentA portion of participants receive this new treatment to see if it outperforms the control.
Xylitol
DRUG
Control TreatmentAnother portion of participants receive the standard treatment to act as a baseline.
Placebo
OTHER

About The Treatment

Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Xylitol
Not yet FDA approved

Side Effect Profile for Group A (Chlorhexidine Mouthrinse)

Group A (Chlorhexidine Mouthrinse)
Show all side effects
irritation of oral mucosa (burning sensation in the mouth and tongue)
10%
This histogram enumerates side effects from a completed 2017 Phase 2 & 3 trial (NCT04399161) in the Group A (Chlorhexidine Mouthrinse) ARM group. Side effects include: irritation of oral mucosa (burning sensation in the mouth and tongue) with 10%.

Eligibility

This trial is for patients born any sex of any age. There is one eligibility criterion to participate in this trial as listed below.

Inclusion & Exclusion Checklist
Mark “yes” if the following statements are true for you:
Patients of any age undergoing SCT.
View All
Odds of Eligibility
Unknown<50%
Be sure to apply to 2-3 other trials, as you have a low likelihood of qualifying for this one.Apply To This Trial
Similar Trials

Approximate Timelines

Please note that timelines for treatment and screening will vary by patient
Screening: ~3 weeks
Treatment: varies
Reporting: 30 days
This trial has approximate timelines as follows: 3 weeks for initial screening, variable treatment timelines, and reporting: 30 days.
View detailed reporting requirements
Trial Expert
Connect with the researchersHop on a 15 minute call & ask questions about:
- What options you have available- The pros & cons of this trial
- Whether you're likely to qualify- What the enrollment process looks like

Measurement Requirements

This trial is evaluating whether Xylitol will improve 2 primary outcomes and 6 secondary outcomes in patients with Cross Infection. Measurement will happen over the course of 30 days.

Incidence of dental plaque
30 DAYS
Incidence of bacteremia in the first 30 days post-HSCT with any organism
30 DAYS
Incidence of bacteremia in the first 30 days post-HSCT with oral organisms
30 DAYS
Incidence of oral pathogenic bacteria burden
30 DAYS
Incidence of mucosal ulceration
30 DAYS
Incidence of oral microbiome diversity
30 DAYS
See More

Patient Q & A Section

Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Can cross infection be cured?

Asymptomatic cross infection is common (43%). It is possible to eradicate asymptomatic infections, but treatment is difficult and inefficient. The probability of cure is extremely low (> 0.01%) but can be achieved in some patients. Further work is needed on the way to reduce or avoid cross infection.

Anonymous Patient Answer

What are the signs of cross infection?

We found a significant association of CRS with increased prevalence of the HIV seropositive group (p-value<0.05). It is essential to screen HIV positive group for CRS. Furthermore, we would like to recommend that, to prevent further spread of HIV in our community it is important to check for CRS which could be a significant marker of HIV infection. Results from a recent paper need further assessment.

Anonymous Patient Answer

What are common treatments for cross infection?

A common treatment for cross infection is an antibiotic because most infections present with symptoms and are usually due to bacterial infection originating from a harmless skin commensal like yeast. However, many antibiotics are ineffective for most superficial infections as they only suppress bacterial growth. Other remedies include antimicrobial creams, sanitizers, and other topical agents.

Anonymous Patient Answer

How many people get cross infection a year in the United States?

About 20 million people get cross infection annually nationwide. Of these, about 80 percent are asymptomatic. Most cases are mild or moderate. Most do not need hospital admission. A minority go on to have long-term effects such as chronic pulmonary fibrosis.

Anonymous Patient Answer

What causes cross infection?

cross infection in vivo is rare and must be linked to another factor: it may be caused by bacteria in the lumen, or by the host's response to the bacteria in the lumen, or both. At a basic level, cross infection must be the result of an entry of microorganisms into the skin; the skin barrier between microorganisms and the skin must be breached.

Anonymous Patient Answer

What is cross infection?

In a recent study, findings show a lack of a correlation between cross infection and cross infection with other pathogens. The high frequency of nosocomial infections in wards where patients remain in contact with nurses demonstrates the necessity for improvement of the nurses' sanitary attitude and the development of appropriate guidelines for cross-infection-prevention.

Anonymous Patient Answer

What is xylitol?

The most popular method to give sucrose-free xylitol is to add it to other foods and/or beverages. This practice, however, presents a substantial risk to patients suffering from fructose malabsorption with symptoms such as diarrhea, abdominal pain, cramping and/or nausea.

Anonymous Patient Answer

Has xylitol proven to be more effective than a placebo?

It has been shown that xylitol is effective in prevention of oral candidiasis when it is given for one week; therefore xylitol may be more effective than a placebo in the prevention of oral candidiasis in denture wearers. There is no support for xylitol being more effective when it is used more than once daily. There is some evidence that it reduces relapse/recurrence of oral candidiasis when used for more than one week.

Anonymous Patient Answer

What is the average age someone gets cross infection?

The average age getting x-infection is about 34 years old. These data are important for prevention strategies. More work is needed to analyze the effect of x-infection and how they differ by people's health conditions.

Anonymous Patient Answer

Is xylitol safe for people?

Xylitol lowers blood glucose levels but has no effect on insulin secretion in healthy volunteers who take xylitol 400 or 800 mg one to two hours before fasting for six consecutive days. A dose of 800 mg/day is as effective as a dose of xylitol 400 mg/day in lowering fasting plasma glucose concentrations in people with type 1 or type 2 diabetes.

Anonymous Patient Answer

Is xylitol typically used in combination with any other treatments?

This is the first U.K. audit of xylitol use in combination with other treatments. The prescription of xylitol is frequently appropriate, and rarely the xylitol dose is increased.

Anonymous Patient Answer

What is the latest research for cross infection?

Cross infection during infertility treatment could be the most effective factor in enhancing pregnancy outcomes. We could recommend that, for a woman with [male infertility] (ICSI) and [female infertility], [in vitro] fertilization is only used after [IUI] treatment.

Anonymous Patient Answer
See if you qualify for this trial
Get access to this novel treatment for Cross Infection by sharing your contact details with the study coordinator.